RxDoctor Payments Data

Michelle Talag, APRN

Family · Seaford, DENPI 1114319738

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 313 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 44 manufacturers, the largest accounting for just 17.5% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,724, 2.1 times the $808 reported in 2021. Among family clinicians in DE with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$6,136in general payments, 2019–2025

Across 313 payments — averaging $19.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • AbbVie$597
  • Lilly USA, LLC$462
  • Pfizer$339
  • Amgen$310
  • AstraZeneca$310
  • plus $3K from 38 others

What the payments were for

  • Food & beverage$6,136100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,136 in reported general payments places this provider in the 90th percentile of 523 family providers in Delaware.

See all family providers in Delaware

Medicare billing

Part B allowed, 2024
$59,577
Medicare patients
276
Services billed
807

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban95$83,153
JardianceEmpagliflozin54$62,196
OzempicSemaglutide28$35,026
RybelsusSemaglutide13$27,673
XareltoRivaroxaban25$27,135
Trelegy ElliptaFluticasone/Umeclidin/Vilanter22$22,162
TradjentaLinagliptin12$16,088
FarxigaDapagliflozin Propanediol12$14,108
Spiriva HandihalerTiotropium Bromide18$12,303
Spiriva RespimatTiotropium Bromide12$9,293
SymbicortBudesonide/Formoterol Fumarate17$6,492
BrilintaTicagrelor12$5,584
Rosuvastatin Calcium269$4,304
Atorvastatin Calcium475$4,190
Albuterol Sulfate HfaAlbuterol Sulfate123$3,331

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat$265$87,57778 claims
PfizerEliquis$339$83,15395 claims
Novo NordiskOzempic, Rybelsus$1,071$62,69941 claims
AstraZenecaFarxiga, Symbicort, Brilinta$310$26,18441 claims
GSKTrelegy Ellipta$93$22,16222 claims
ANI Pharmaceuticals, Inc.Valsartan$25$1,06133 claims
AbbVieSynthroid$597$1,05945 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 523 family providers in Delaware.

Other family in Seaford

See the full list for Delaware

Where these figures come from

Is this you, or does something look wrong? →